ITEM VIEW

Administration of depolarizing muscle relaxants after non-depolarizer reversal: when is it safe?

dc.contributor.authorDe Roubaix, J. A. M.en_ZA
dc.date.accessioned2011-03-18T14:57:44Z
dc.date.available2011-03-18T14:57:44Z
dc.date.issued1982-04
dc.identifier.citationDe Roubaix, J.A.M. 1982. Administration of depolarizing muscle relaxants after non-depolarizer reversal: when is it safe? . S Afr Med J, 71(4):583-584.en_ZA
dc.identifier.issn2078-5135 (online)
dc.identifier.issn0256-9574 (print)
dc.identifier.urihttp://hdl.handle.net/10019.1/7618
dc.descriptionCITATION: De Roubaix, J.A.M. 1982. Administration of depolarizing muscle relaxants after non-depolarizer reversal: when is it safe? . S Afr Med J, 71(4):583-584.en_ZA
dc.descriptionThe original publication is available at http://www.samj.org.zaen_ZA
dc.description.abstractENGLISH ABSTRACT: In the light of studies on the duration of action and pharmacokinetics of intravenous neostigmine, it is recommended that, depending upon the dosage administered, at least 1 hour should elapse before a depolarizer can safely be given after neuromuscular reversal with neostigmine, and at least 90-120 minutes after reversal with physostigmine. It is suggested that a diluted test dose of depolarizer be given first, and its effect monitored with a peripheral nerve stimulator because fasciculations will not occur.en_ZA
dc.format.extent2 pagesen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherHealth & Medical Publishing Groupen_ZA
dc.subjectNeuromuscular depolarizing agentsen_ZA
dc.subjectLeptocucaresen_ZA
dc.subjectIntravenous therapyen_ZA
dc.titleAdministration of depolarizing muscle relaxants after non-depolarizer reversal: when is it safe?en_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher’s version
dc.rights.holderSouth African Medical Journalen_ZA


Files in this item

Thumbnail

This item appears in the following Collection(s)

ITEM VIEW